XoNovo

Company Overview

Snapshot

Founded in August 2013 by Kenneth Hensley and Rafi Gidron, XoNovo operated with 11–50 employees. The company secured funding across one round from FutuRx, before ceasing operations in September 2019.

Business overview

XoNovo is a preclinical-stage biopharmaceutical company focused on developing small-molecule therapeutics to prevent the progressive loss of neuronal function in various neurodegenerative diseases. The company's core technology involves selective modulation of autophagy and axonal transport machinery in neurons, with its lead drug, XN001, extensively tested in models for Batten disease, Alzheimer's disease, glioblastoma, muscular dystrophy, and tuberous sclerosis. XoNovo operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, targeting the pharmaceutical market.

Company Intelligence Q&A

What is XoNovo's primary focus?

XoNovo is a preclinical-stage biopharmaceutical company focused on developing small-molecule therapeutics to prevent the progressive loss of neuronal function across multiple neurodegenerative diseases.

When was XoNovo founded?

XoNovo was founded in August 2013 by Kenneth Hensley and Rafi Gidron.

What was the status of XoNovo's operations?

XoNovo ceased to operate in September 2019.

What was the lead drug candidate for XoNovo?

XoNovo's short-term focus was on its lead drug, XN001, intended for filing an investigational new drug application for Batten disease (BD), also known as neuronal ceroid lipofuscinoses.